After bagging Yescarta exec as CMO, T-cell biotech NexImmune files for $86M IPO

Just a few days after NexImmune bumped up its credentials with the hiring of Gilead Sciences and Kite Pharma alum Robert Knight, M.D., the T-cell biotech is now gunning for an $86 million IPO.

The startup wants the cash to boost its work on immunotherapy, with its platform designed to employ the body’s own T cells to generate a potent and durable immune response that mimics natural biology.